A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02914938

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:10.848026+00:00

Published At

2023-05-09T00:00:00+00:00

Record Updated At

2023-05-09

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Follicular Lymphoma (FL)", "Marginal Zone B Cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "High Grade Non-Hodgkin\u0027s Lymphoma", "Mantle Cell Lymphoma (MCL)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2023-05-09"

protocolSection.identificationModule.nctId

"NCT02914938"

protocolSection.identificationModule.officialTitle

"A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Chronic Lymphocytic Leukemia (CLL) (protocolSection.conditionsModule.conditions)
• Small Lymphocytic Lymphoma (SLL) (protocolSection.conditionsModule.conditions)
• Follicular Lymphoma (FL) (protocolSection.conditionsModule.conditions)
• Marginal Zone B Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Diffuse Large B-cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
• High Grade Non-Hodgkin's Lymphoma (protocolSection.conditionsModule.conditions)
• Mantle Cell Lymphoma (MCL) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.